HFEA Licence Committee Meeting 7 November 2013 Finsbury Tower, Bunhill Row, London, EC1Y 8HF
|
|
- Lucy Hunter
- 5 years ago
- Views:
Transcription
1 Minutes Item 8 HFEA Licence Committee Meeting 7 November 2013 Finsbury Tower, Bunhill Row, London, EC1Y 8HF Centre 0101 (CARE Nottingham) Grade A Incident IN03434 and the preliminary findings of another reported incident Members of the Committee: Sally Cheshire (lay) Chair Gemma Hobcraft (lay) Bishop Lee Rayfield (lay) (video) Debbie Barber (professional) Andy Greenfield (professional) Committee Secretary: Lauren Crawford Legal Adviser: Graham Miles, Morgan Cole Observing: Sam Hartley, Head of Governance and Licensing, HFEA Juliet Tizzard, Interim Director of Strategy, HFEA Declarations of Interest: members of the Committee declared that they had no conflicts of interest in relation to this item. The following papers were considered by the Committee: Executive Summary HFEA s root cause analysis Centre s incident investigation report Person Responsible s statement regarding the continued suitability and use of Genesis Genetics Europe Service Level Agreement between centre no 0101 and Genesis Genetics Europe Genesis Genetics Europe incident report Genesis Genetics Europe audit of 2013 de novo PGD cases Previous Executive Licensing Panel minutes: a) 14 January 2010 interim inspection report b) 15 June 2012 licence renewal report Previous Licence Committee minutes: 21 January 2010 grade A incident 30 April 2010 grade A incident 27 May 2010 grade A incident 24 June 2010 grade A incident 11 June 2012 grade A incident
2 The Committee also had before it: HFEA Protocol for the Conduct of Licence Committee Meetings and Hearings 8th edition of the HFEA Code of Practice Human Fertilisation and Embryology Act 1990 (as amended) Decision trees for granting and renewing licences and considering requests to vary a licence (including the PGD decision tree) Guidance for members of Authority and Committees on the handling of conflicts of interest approved by the Authority on 21 January Guidance on periods for which new or renewed licences should be granted Standing Orders and Instrument of Delegation Indicative Sanctions Guidance HFEA Directions Guide to Licensing Compliance and Enforcement Policy Policy on Publication of Authority and Committee Papers Consideration 1. The Committee noted that this is an incident reporting a possible PGD misdiagnosis. The initial incident information relating to the incident being considered here describes a highly specialised diagnostic test (for a de novo mutation) and not the usual PGD analysis. 2. The Committee noted that the centre s initial investigation revealed that operator error may be the root cause but this was still under investigation. 3. The Committee noted that the centre has previously had a number of PGD - related incidents. 4. The Committee noted that further to incident IN03434 another possible misdiagnosis has been reported. The information collected so far for this incident has also been submitted to the Licence Committee. 5. The Committee noted that the Genesis Genetics Europe reported the incident to its accrediting body, Clinical Pathology Accreditation (CPA). To ensure that the incident was thoroughly considered by the appropriate experts, the executive endeavoured to arrange a joint incident inspection with their accrediting body.
3 6. The Committee noted that the HFEA Root Cause Analysis (RCA) for incident IN03434 states that the root cause of the incident could be: Insufficient oversight around the scheduling of a complex test. Staff not adhering to processes documented in SOPs. The absence of formal training and competence assessment of staff in relation to rarely performed/complex tests. Written and verbal communications not clear in relation to the type of PGD case (i.e. de novo). 7. The Committee noted that the Executive has taken steps to ensure a full and proper investigation takes place including holding a crisis management meeting to discuss the options for this centre. The Executive has also fully engaged with the Centre and the Clinical Pathology Accreditation (CPA). 8. The Committee noted the receipt of the initial reports for another possible PGD-related incident at the same centre. This information was supplied as it is relevant to incident IN Decision 9. The Committee noted that, although they had a lot of information before them, neither incident had been fully investigated as yet. The Committee recognised that incident IN03434 involves specialist techniques and obtaining experts in that field may be adding to time taken to get the report finalised. 10. The Committee decided to adjourn the item for receipt of further information. This information should include: a. Final investigation reports for both incidents b. Further information regarding PGD diagnosis error rates across the sector for comparison c. Further information about Genesis Genetics Europe including how many other centres use their labs for PGD; do they have other labs d. Clarity on the status of the patients affected by the incident 11. The Committee noted that although the item was adjourned they would expect an update on the status of both of these incidents at the next meeting of the Licence Committee (January 2014). The Committee is concerned by the frequency of incidents regarding PGD happening at this centre and the potential risks to current patients and unborn children.
4 12. The Committee urged the centre and the Executive to provide this extra information as soon as possible, given the serious nature of these incidents. Signed: Date: 21/11/2013 Sally Cheshire (Chair)
5 Incident Investigation Report Centre no 0101 incident number IN03434 Since October 2009 the HFEA has normally published A grade incident reports and the associated Licence Committee minutes on our website. Background of the centre and the licencing history CARE Nottingham is a privately run unit and provides a wide range of fertility treatments including pre-implantation genetic screening and diagnosis (PGS and PGD). The centre carries out approximately 2000 cycles of licenced treatment a year. The centre was first established in 1985 and a licence renewal inspection last took place on 28 February 1 March At the time of inspection one critical non-compliance, two major non-compliances and seven other non-compliances were noted. The Executive Licencing Panel (ELP) granted the centre a four year licence with no additional conditions. The Person Responsible (PR) is also the Laboratory Manager and is an experienced embryologist who has completed the HFEA PR entry programme. In July and November 2009 the centre reported two (unrelated see footnote) A grade incidents regarding PGD misdiagnosis 1. In 2011 the centre reported a further incident initially categorised as an A grade incident resulting from a PGD misdiagnosis. The HFEA understands that those directly affected by the incident are taking legal action. The HFEA is informed that the testing laboratory has since performed further analysis of the samples to suggest that other factors, rather than a PGD misdiagnosis, are relevant to the ultimate outcome of the treatment. This remains under review by the centre and the HFEA. Summary Incident Description & Consequences A couple had a treatment cycle of PGD in July 2013, testing for Neurofibromatosis 2. Ten embryos were biopsied on Day 3 and the cells were sent to Genesis Genetics (Europe) 3 for analysis. Two biopsies returned a result of unaffected/normal, three indicated the source embryos were affected and 5 provided insufficient data in the report for a result to be given. 1 One incident was a single gene disorder tested for by PCR (polymerase chain reaction), the second was a chromosomal translocation case tested by FISH. The two analyses were carried out at different testing labs Genesis Genetics Institute and the Bridge Genoma. 2 Neurofibromatosis Type 1 (NF1) also known as von Recklinghausen NF or Peripheral NF is an autosomal dominant disorder occurring in 1:3,500 births. NF1 is characterised by multiple cafe-au-lait spots and fibromatous tumors on or under the skin. Enlargement and deformation of bones and curvature of the spine (scoliosis) may also occur. Occasionally, tumors may develop in the brain, on cranial nerves, or on the spinal cord. About 50% of people with NF also have learning disabilities. 3 Genesis Genetics (Europe) is the European subsidiary of the Genesis Genetics Institute, a large PGD service provider based in Detroit, USA. Genesis Genetics (Europe) provide PGD services to CARE Nottingham through a third party agreement. Genesis Genetics (Europe) occupy laboratory space within the CARE Nottingham building to allow them to do this. Doc name: Template RCA incident investigation report Doc reference: CT-14 Version: 1.1 TRIM reference: 2010/03639 Release date: 20 June 2011
6 On 03 July 2013, in conjunction with the embryo development information, one of the apparently unaffected embryos was transferred to the woman and one was frozen for future use. Three of the no result embryos were re-biopsied at the blastocyst stage and frozen for possible future use pending the results of testing of the blastocyst biopsies by Genesis Genetics (Europe). A positive pregnancy test was performed on 15 July On 16 July 2013, Genesis Genetics (Europe) contacted the PR of the centre to inform her that on re-reading the original testing data from the Day 3 biopsies, they had found that the data had been interpreted incorrectly and the results report issued by Genesis Genetics (Europe) to CARE Nottingham on 2 July 2013 had given an incorrect diagnosis for the embryos. Therefore the embryo that was transferred to the woman and the embryo that was frozen for future use in treatment, which were initially interpreted as being unaffected, were actually affected with the genetic disease, while the three embryos that had been originally interpreted as affected and which had been allowed to perish, were in fact unaffected. Background to PGD analysis for do novo cases Usually in PGD, an affected reference child or close relative is available so that prior to the PGD IVF cycle, the mutated gene can be linked during test optimisation to STR 4 markers on the chromosome bearing the mutation, thus identifying the affected allele haplotype. In PGD this is termed setting phase. This allows testing to investigate the presence of several STR markers linked to the mutation, that is haplotype testing. This is undertaken to improve the accuracy and reliability of the test. However, in a first cycle de novo 5 case such as the case involved in this incident, a reference individual is not available. This prevents phase setting prior to testing of the embryo biopsies on the day the procedure is undertaken. Instead, phase has to be set on the day by performing direct sequencing of the mutation site using whole genome amplified (WGA) DNA from each of the embryo biopsies. The sequencing results are then correlated with the results of informative STR marker testing which is run in parallel. Once an embryo is clearly identified bearing the mutation, the parental STR markers linked to the mutation can be identified. Therefore setting phase on case day is reliant on good quality direct mutation sequencing, which can be complicated by allelic drop out (ADO) because single cell PGD biopsy samples frequently do not amplify all loci. Operator experience and competence is also essential since the sequencing and informative marker testing data must be interpreted on the day of testing to assign phase accurately. Thus de novo PGD haplotype testing is recognised as being more technically demanding than normal PGD testing where setting phase can be accomplished before the case day using samples from affected relatives. Incident type: PGD misdiagnosis 4 A short tandem repeat (STR) is a type of DNA polymorphism where short sequences of DNA are repeated. STRs are usually considered junk DNA because they are introns and do not code for protein. The number of times a DNA sequence is repeated for a given STR is variable between different individuals and thus, STRs are often useful for forensic or genealogical studies. 5 A de novo mutation refers to a genetic mutation that neither parent possessed or transmitted. Doc name: Template RCA incident investigation report Doc reference: CT-14 Version: 1.1 TRIM reference: 2010/03639 Release date: 20 June 2011
7 Specialty: Effect on patient: PGD testing laboratory Significant impact on couple who have been informed that an affected embryo has been selected and transferred resulting in an on-going pregnancy. Severity level: HFEA Grade A Terms of reference To identify the root causes and key learning from this incident and use this information to significantly reduce the likelihood of future harm to patients. Scope and Level of Investigation HFEA Root Cause Analysis Incident inspection including document review Investigation by Genesis Genetics (Europe) (included in the report from centre 0101) The executive has taken longer than usual to schedule the incident inspection in an effort to initiate a joint inspection with the CPA 6. Unfortunately the executive were not able to perform a joint inspection as the CPA was unable to participate at this stage. However the CPA will be carrying out its own investigation and is keen to receive input from the HFEA regarding this incident 7. Chronology of events - See table overleaf Notable Practice Actions were taken to inform the couple of the incident in an open and honest way. The incident was reported in line with the HFEA s incident reporting requirements. The centre ensured that staff from the testing laboratory were available on the day of inspection and all participants contributed positively to the inspection and subsequently. The Laboratory Director from Genesis Genetics Europe carried out an audit of previous de novo cases 8. Involvement and support of Patient and Relatives Documentation provided by the PR confirms that contact and communication has been maintained with the patient throughout this investigation. Care and service delivery problems at Genesis Genetics (Europe) Genesis Genetics (Europe) SOP states that the Case Data Reader - a document designed to allow the compilation and display, in an easy to interpret format, of the results of STR marker testing and direct mutation screening for each embryo - should be completed at least 7 days ahead of the receipt of embryo biopsies on the case day. This ensures adequate time to request and receive any missing information and items. Further to this, the SOP states the PGD Pre-Case checklist should be signed off by the laboratory scientist and approved by the laboratory manager once the Case Data Reader is completed. On the day the biopsies were received from centre 0101, a laboratory scientist at Genesis Genetics (Europe) created the Case Data Reader rather than it being 6 Clinical Pathology Accreditation (CPA) is the organisation which accredited Genesis Genetics (Europe). 7 The CPA carried out their inspection on 22 October Audit looked back at the previous three years worth of cases. Copy of audit findings provided in bundle. Doc name: Template RCA incident investigation report Doc reference: CT-14 Version: 1.1 TRIM reference: 2010/03639 Release date: 20 June 2011
8 completed 7 days in advance of receiving the samples. This is a breach of the laboratory s SOP. The Day Case Reader was also completed incorrectly since it did not allow the inclusion of direct mutation sequencing data. A further breach occurred as the completed Pre-Case checklist was not signed off by the laboratory manager at Genesis Genetic (Europe). The senior member of staff at Genesis Genetics (Europe) who reviewed the Case Data Reader did not read/scroll down the whole document and failed to see the note mutation is de novo at the bottom of the document. Therefore this member of staff did not realise this was a de novo case. The laboratory scientist at Genesis Genetic (Europe) performing the testing incorrectly set phase when interpreting the testing results. Contributory Factors At the time of this incident the laboratory staff at Genesis Genetics (Europe) did not undergo specific competency assessment regarding de novo cases. The senior scientist who carried out the Case Data Reader review and who was available to provide advice to the laboratory scientist performing the test, was working in a Genesis Genetics laboratory in London while the biopsy testing was being performed in a laboratory in Nottingham. Information explaining this was a de novo case did not alert the senior scientist carrying out the Case Data Reader review, probably because it was not displayed in a prominent position. Nor did any of the communications between the staff highlight that this was a de novo case. Root Causes Insufficient oversight around the scheduling of a complex test. Staff not adhering to processes documented in SOPs. The absence of formal training and competence assessment of staff in relation to rarely performed/complex tests. Written and verbal communications not clear in relation to the type of PGD case (i.e. de novo). Lessons Learned It is important to ensure a high level of alertness is attached to any rare/unusual test or procedure carried out either for or on a patient. Sufficient information should be communicated to the team carrying out the test/procedure in a timely fashion. This should include reference to the appropriate SOPs, specific task allocation and more importantly to discuss what to do if conditions are not optimal to continue with the test/procedure. Recommendations Genesis Genetics (Europe) has initiated a number of corrective actions to minimise the reoccurrence of a similar incident 9 : All staff will be trained to clearly note that for de novo cases, without reference or phase on a previous cycle, phase must be set with direct sequencing analysis of mutation analysis. A specific training event will be scheduled. Only when competence is assured will staff be signed off to analyse data and report results in de novo cases. 9 Please see section 7 corrective actions of the Genesis Genetics Europe report for full text. Doc name: Template RCA incident investigation report Doc reference: CT-14 Version: 1.1 TRIM reference: 2010/03639 Release date: 20 June 2011
9 All case family ID for de novo cases will include de novo in the unique family identifier. SOPs and database entries will be amended accordingly. All de novo cases run by Genesis Genetics (Europe) in future will be performed on biopsy samples from vitrified embryos in order to allow additional case reader proof reading or additional markers/sequencing to be run. Genesis Genetics (Europe) users will be notified by the Laboratory Director and protocols amended. All de novo Case Data Readers will be created at least one week in advance of case day and will be independently proofed by a senior scientist. Case notes will be moved to the top of the Case Data Reader. All de novo cases will require a third read by the Genesis Genetics (Europe) laboratory manager or the Genesis Genetics (Detroit) laboratory manager in their absence. Protocols will be amended. Further formalised training in sequencing has been requested by a member of staff and Genesis Genetics (Europe) are fully supportive in providing this. This further training will consist of a formal training program in sequencing analysis at Genesis Genetics (Detroit). However as the HFEA has no direct regulatory powers as regards (notwithstanding the centre s third party agreement) Genesis Genetics (Europe) the executive recommends that the PR provides to the Licence Committee a written statement explaining why she, as the PR at the centre, is satisfied in allowing Genesis Genetics (Europe) to continue to PGD analysis on behalf of CARE Nottingham patients. The PR has now provided a written statement as to why she is satisfied that Genesis Genetics Europe is a safe and suitable laboratory to carry out embryo testing on the centre s behalf. The executive consider that this is insufficient. The statement does not include information on how the PR will monitor and consider as complete the corrective actions 10 Genesis Genetics intend to carry out in relation to this incident. Further work should be undertaken in relation to this issue. For the PR to demonstrate that Genesis Genetics Europe is carrying out suitable practices 11 in the course of the activities they carry out on behalf of the centre, the executive recommend that the PR provides; an action plan as to how she will monitor the laboratory s progress against their remedial actions this action plan should contain well defined timeframes to ensure that these actions are monitored in a timely fashion a suitable audit trail of evidence as referenced from Genesis Genetics investigation report Although it is not entirely clear at this point what the root cause of one of the incidents at Genesis Genetics was, it is clear from the evidence contained in this report that in at least one of the two incidents that have been reported to the HFEA, there were some shortcomings in the processes at Genesis Genetics. In light of this and the lack of assurance, in the executive s view, that these inadequacies have been properly addressed and therefore the 10 The corrective actions are mentioned in this section of the report and in full in Genesis Genetics Europe report (section 7) 11 The PR under SLC T2 has a duty to ensure that suitable practices are being used in the course of activities authorised by her licence Doc name: Template RCA incident investigation report Doc reference: CT-14 Version: 1.1 TRIM reference: 2010/03639 Release date: 20 June 2011
10 likelihood of any further serious incidents of this nature are reduced, the Executive recommends that the PR provides further assurances. The executive consider it would be disproportionate and unfair to CARE patients to suspend the centre s PGD/PGS programme. However the continued use of Genesis Genetics in the absence of assurances that the remedial actions have been properly implemented and thus the possibility that further patients and their embryos may face similar risks to those patient s affected by the reported incidents, the executive recommends that the Licence Committee make a direction using their powers under section 24(13)(a) and (b) of the HFE Act 1990 (as amended) to direct the PR not to use the services of Genesis Genetics Europe for the purpose of embryo testing (for PGD & PGS). When this evidence is provided to the satisfaction of the executive we will submit the evidence to the Licence Committee with an appropriate recommendation. Authors Paula Nolan (Clinical Governance Lead/Inspector) Date 17 September 2013 Doc name: Template RCA incident investigation report Doc reference: CT-14 Version: 1.1 TRIM reference: 2010/03639 Release date: 20 June 2011
11 Chronology of events Date & Time Event 06/12/2012 Couple were counselled by Genesis Genetics Institute (Detroit, USA) counsellor on the limitations of setting genetic phase day. 28/06/2013 Patient undergoes oocyte retrieval. 01/07/2013 Embryo biopsy performed and 10 embryos were biopsied. The cells were sent to Genesis Genetics Europe for testing. Two of these returned a result of unaffected/normal, 3 results shown to be affected and 5 had insufficient data on the report for a result to be given. 03/07/2013 In conjunction with the embryo development information one of the unaffected embryos was transferred, and one was frozen for future use. 15/07/2013 Positive pregnancy test. 16/07/2013 The testing lab, Genesis Genetics Europe, contacted the PR of the centre to inform her that on re-reading the original data from the Day 3 biopsy they had found that the results had been interpreted incorrectly and the results report issued had given incorrect diagnosis for the embryos. 17/07/2013 Centre report incident to the HFEA. Doc name: Template RCA incident investigation report Doc reference: CT-14 Version: 1.1 TRIM reference: 2010/03639 Release date: 20 June 2011
12 17/07/2013 Patient was contacted to invite her and her partner to attend a meeting with the Medical Director and the Nurse Manager/PGD Nurse. 19/07/2013 Couple attended centre and situation explained to them. 22/07/2013 HFEA Management Review. 22/07/2013 Telephone discussion with the PR (with the HFEA Clinical Governance Lead/Inspector). How is she, as the PR, assured that an incident of this nature will not happen again? What reassurance/changes in practice have the testing lab provided to minimise the risk of reoccurrence? The PR to provide written reassurance to the Executive as a matter of urgency. 24/07/2013 from PR with further information about the incident including assurances from the Genesis Genetics Europe, laboratory manager, explaining what further measure have been put in place to minimise the reoccurrence of a similar incident raking place. 2/08/2013 Preliminary incident report received from the PR. 2/09/2013 Full report including Genesis Genetics Europe investigation sent by the PR. 13/09/2013 HFEA incident inspection. Doc name: Template RCA incident investigation report Doc reference: CT-14 Version: 1.1 TRIM reference: 2010/03639 Release date: 20 June 2011
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
HFEA Licence Committee Meeting 9 January 2014 Finsbury Tower, Bunhill Row, London, EC1Y 8HF
Minutes Item 7 HFEA Licence Committee Meeting 9 January 2014 Finsbury Tower, 103-105 Bunhill Row, London, EC1Y 8HF Centre 0101 (CARE Nottingham) - Grade A Incident Report Members of the Committee: Andy
More informationHuman Fertilisation and Embryology Authority. Minutes of the Licence Committee
Human Fertilisation and Embryology Authority Minutes of the Licence Committee Meeting held at Finsbury Tower, 103-105 Bunhill Row, London, EC1Y 8HF on 16 July 2015 Minutes item 2 Centre 0101 (CARE Nottingham)
More informationFriday, 13 January 2017 HFEA, 10 Spring Gardens, London SW1A 2BU
Friday, 13 January 2017 HFEA, 10 Spring Gardens, London SW1A 2BU Panel members Juliet Tizzard (Chair) Howard Ryan Trisram Dawahoo Members of the Executive Bernice Ash Secretary Director of Strategy & Corporate
More informationHFEA Executive Licensing Panel Meeting 5 September 2014 Finsbury Tower, Bunhill Row, London, EC1Y 8HF
Minutes Item 1 HFEA Executive Licensing Panel Meeting 5 September 2014 Finsbury Tower, 103-105 Bunhill Row, London, EC1Y 8HF Centre 0030 (Herts and Essex Fertility Centre) Renewal Treatment & Storage Inspection
More informationResearch Licence Renewal Inspection Report
Research Licence Renewal Inspection Report Project Title The vitrification of blastocysts following biopsy at the earlycleavage stage or blastocyst stage of embryo development A Pilot Study Research Licence
More informationHFEA Executive Licensing Panel Meeting 31 October 2014 Finsbury Tower, Bunhill Row, London, EC1Y 8HF
Minutes Item 1 HFEA Executive Licensing Panel Meeting 31 October 2014 Finsbury Tower, 103-105 Bunhill Row, London, EC1Y 8HF Centre 0019 (Aberdeen Fertility Centre) Renewal Treatment & Storage Inspection
More informationInitial licence Inspection Report
Initial licence Inspection Report Date of Inspection: 13 February 2013 Purpose of inspection: New licence application Length of inspection: 8 hours Inspectors: Susan Jolliffe Andrew Leonard Victoria Mills
More informationMonday, 22 January 2018 HFEA, 10 Spring Gardens, London SW1A 2BU
Monday, 22 January 2018 HFEA, 10 Spring Gardens, London SW1A 2BU Panel members Members of the Executive External adviser Caylin Joski-Jethi (Chair) Jessica Watkin Helen Crutcher Bernice Ash Nana Gyamfi
More informationAdverse incidents in fertility clinics: lessons to learn
Adverse incidents in fertility clinics: lessons to learn January-December 2014 www.hfea.gov.uk Adverse incidents in fertility clinics: lessons to learn Human Fertilisation and Embryology Authority 3 Contents
More informationHuman Fertilisation and Embryology Authority. Minutes of the Executive Licensing Panel
Human Fertilisation and Embryology Authority Minutes of the Executive Licensing Panel Meeting held at HFEA, Finsbury Tower, 103-105 Bunhill Row, London, EC1Y 8HF on 27 February 2015 Minutes item no. 1
More informationLicence Committee - minutes
Licence Committee - minutes Centre 0157 (Assisted Reproduction and Gynaecology Centre) Renewal Inspection report Monday, 20 June 2016 HFEA, Level 2, 10 Spring Gardens, London, SW1A 2BU Committee members
More informationFriday, 22 September 2017 HFEA, 10 Spring Gardens, London SW1A 2BU
Friday, 22 September 2017 HFEA, 10 Spring Gardens, London SW1A 2BU Panel members Hannah Verdin (Chair) Howard Ryan Jessica Watkin Head of Regulatory Policy Report Developer Policy Manager Members of the
More informationResearch Renewal Inspection Report
Research Renewal Inspection Report Date of Inspection: 12 April 2011 Purpose of inspection: Renewal of Research Licence Length of inspection: 6 hours Inspectors Dr Andrew Leonard Mr Parvez Qureshi Inspection
More information15. Procuring, processing and transporting gametes and
15. Procuring, processing and transporting gametes and embryos Version 6.0 On this page: : Extracts from the HFE Act Directions HFEA guidance: Documented procedures: general Patient selection and procurement
More informationExecutive Licensing Panel - minutes
Executive Licensing Panel - minutes Centre 0342 (Concept Fertility) Renewal Inspection Report Friday, 27 January 2017 HFEA, 10 Spring Gardens, London SW1A 2BN Panel members Juliet Tizzard (Chair) Paula
More informationFriday, 14 July 2017 HFEA, 10 Spring Gardens, London SW1A 2BU
Friday, 14 July 2017 HFEA, 10 Spring Gardens, London SW1A 2BU Panel members Juliet Tizzard (Chair) Anjeli Kara Jessica Watkin Director of Strategy & Corporate Affairs Regulatory Policy Manager Policy Manager
More informationHuman Fertilisation and Embryology Authority 10 Spring Gardens London SW1A 2BU t e w
Edition 8.0 First published October 2009 Revised April 2010, April 2011, October 2011, April 2012, October 2013, October 2014, April 2015, October 2015, July 2016, May 2017, October 2017 Human Fertilisation
More informationFriday, 25 August 2017 HFEA, 10 Spring Gardens, London SW1A 2BU
Friday, 25 August 2017 HFEA, 10 Spring Gardens, London SW1A 2BU Panel members Hannah Verdin (Chair) Anna Coundley Howard Ryan Head of Regulatory Policy Information Access and Policy Manager Report Developer
More informationLicence Renewal Inspection Report for Treatment and Storage Centres. Brentwood Fertility Centre 0165
Licence Renewal Inspection Report for Treatment and Storage Centres Brentwood Fertility Centre 0165 Date of Inspection: June 29 th 2006 Date of Licence Committee: October 11 th 2006 Page 1 of 22 CENTRE
More informationRegulating mitochondrial donation: seeking expert views. Background document
Regulating mitochondrial donation: seeking expert views Background document June 2015 Contents Introduction 3 What we need from you 3 Licensing mitochondrial donation 4 Licensing the clinic to undertake
More informationResearch Licence Inspection Report
Research Licence Inspection Report Project Title Research licence Number Person Responsible Nominal Licensee Inspection type Date application fee paid A novel approach for extracting cells during embryo
More informationLicence Committee - minutes
Licence Committee - minutes Centre 0338 (Reproductive Health Group) Interim Thursday, 11 January 2018 HFEA, 10 Spring Gardens, London, SW1A 2BU Committee members Lee Rayfield (Chair) Ruth Wilde Kate Brian
More informationDate of birth: / / Date of birth: / /
Name (Female): Partner s name: Date of birth: / / Date of birth: / / IVF Number: Background Information An individual s genetic information is packaged into strings of DNA called chromosomes. Normal human
More informationOrganisation of the PGD Centre. Overview. Setting up a PGD centre
Organisation of the PGD Centre Joyce Harper Chair of the ESHRE PGD Consortium Overview Setting up a PGD Centre Organisation of the PGD Centre Preparation for clinical PGD Misdiagnosis Accreditation External
More informationExecutive Summary for Executive Licensing Panel 20 May Dr Kamal Ahuja. Follow-up inspection 14 April 2010
Summary for Licensing Panel 20 May 2010 Centre number 0011 Centre name The London Sperm Bank Person Responsible Dr Kamal Ahuja Background Follow-up inspection 14 April 2010 1. The London Sperm Bank underwent
More informationStatutory Approvals Committee minutes
Statutory Approvals Committee minutes Item 2 Centre 0102 (Guys Hospital) Pre-implantation Genetic Diagnosis (PGD) application for Blepharophimosis, Ptosis and Epicanthus Inversus Syndrome types 1 & 2 (BPES
More informationDate of birth: / / Date of birth: / /
Name (Female): Partner s name: Date of birth: / / Date of birth: / / IVF Number: Background Information An individual s genetic information is packaged into strings of DNA called chromosomes. Normal human
More informationResearch Licence Inspection Report
Research Licence Inspection Report Project Title Studies of embryo development and metabolism Centre Name Assisted Conception Unit, Ninewells Hospital and Medical School Centre Number Centre 0004 Research
More informationEducation and Training Committee 15 November 2012
Education and Training Committee 15 November 2012 Review of the process of approval of hearing aid dispenser pre-registration education and training programmes. Executive summary and recommendations Introduction
More informationInterim Inspection Report. The Bridge Centre 0070
Interim Inspection Report The Bridge Centre 0070 Date of Inspection: 4 th March 2008 Date of Licence Committee: 11 th September 2008 Version: 0 Page 1 of 22 CENTRE DETAILS Centre Name The Bridge Centre
More informationINTRACYTOPLASMIC SPERM INJECTION
1 Background... 2 2 Male Factor Infertility... 2 3 ICSI... 3 4 Surgical sperm aspiration... 4 5 What is the chance of success?... 6 6 What are the risks?... 7 M Rajkhowa, October 2004 Authorised by V Kay
More informationIPC Athletics Classification Rules and Regulations
IPC Athletics Classification Rules and Regulations February 2013 International Paralympic Committee Adenauerallee 212-214 Tel. +49 228 2097-200 www.paralympic.org 53113 Bonn, Germany Fax +49 228 2097-209
More informationSection 32: BIMM Institute Student Disciplinary Procedure
Section 32: BIMM Institute Student Disciplinary Procedure Introduction Academic Development & Quality Assurance Manual This Student Disciplinary Procedure provides a framework for the regulation of BIMM
More informationASSISTED CONCEPTION NHS FUNDED TREATMENT FOR SUBFERTILITY ELIGIBILITY CRITERIA & POLICY GUIDANCE
ASSISTED CONCEPTION NHS FUNDED TREATMENT FOR SUBFERTILITY ELIGIBILITY CRITERIA & POLICY GUIDANCE Version 1.0 Page 1 of 11 MARCH 2014 POLICY DOCUMENT VERSION CONTROL CERTIFICATE TITLE Title: Assisted Conception
More informationCARIBX (UK) LIMITED. Environmental, Health and Safety Management System. Revision: 00 APRIL 2011
CARIBX (UK) LIMITED Environmental, Health and Safety Management System Revision: 00 APRIL 2011 Document Details and Issue Record Rev No. Details Date Author Checked Text 00 Draft 01/04/2011 CJMD Calcs
More informationPreimplantation Genetic Diagnosis (PGD) in Western Australia
Preimplantation Genetic Diagnosis (PGD) in Western Australia Human somatic cells have 46 chromosomes each, made up of the 23 chromosomes provided by the egg and the sperm cell from each parent. Each chromosome
More informationWomen s consent to the use and storage of eggs or embryos for surrogacy
Women s consent to the use and storage of eggs or embryos for surrogacy HFEA WSG form About this form This form is produced by the Human Fertilisation and Embryology Authority (HFEA), the UK s independent
More informationHearing aid dispenser approval process review Introduction Hearing aid dispenser data transfer... 6
Hearing aid dispenser approval process review 2010 11 Content 1.0 Introduction... 4 1.1 About this document... 4 1.2 Overview of the approval process... 4 2.0 Hearing aid dispenser data transfer... 6 2.1
More informationMinutes of Authority meeting 20 January 2016
Minutes of Authority meeting 20 January 2016 Strategic delivery: Setting standards Increasing and informing choice Demonstrating efficiency economy and value Details: Meeting Authority Agenda item 2 Paper
More informationCompliance activities 2014/15: analysis of inspection findings
Compliance activities 2014/15: analysis of inspection findings Strategic delivery: Setting standards Increasing and informing choice Demonstrating efficiency economy and value Details: Meeting Authority
More informationThe Rosie Hospital, Cambridge (0051)
Human Fertilisation and Embryology Authority Report of Renewal inspection at The Rosie Hospital, Cambridge (0051) Date of Inspection 02.05. 2006 Date of Licence Committee 10 July 2006 1 Contents Key facts
More informationAuthority Paper. Minutes of Authority meeting 5 March Decision
Authority Paper Paper Title Minutes of Authority meeting 5 March 2014 Agenda Item 2 Paper Number [HFEA (14/05/2014) 717] Meeting Date 14 May 2014 Author For information or decision? Recommendation Charlotte
More informationGOVERNING BOARD. Assisted Conception (IVF): Review of access criteria. Date of Meeting 21 January 2015 Agenda Item No 13. Title
GOVERNING BOARD Date of Meeting 21 January 2015 Agenda Item No 13 Title Assisted Conception (IVF): Review of access criteria Purpose of Paper The SHIP (Southampton, Hampshire, Isle of Wight and Portsmouth)
More informationMolecular blood spot performance monitoring
Molecular blood spot performance monitoring Description This management procedure document details the processes involved in determining the performance standard of each participating laboratory in the
More informationPGS Embryo Screening
PGS Embryo Screening Contents What are chromosomes? 3 Why should I consider chromosome testing of my embryos? 3 Embryo testing using preimplantation genetic screening (PGS) 4 How does PGS and the chromosome
More informationCare and Social Services Inspectorate Wales
Care and Social Services Inspectorate Wales Service Regulation and Inspection Guidance on inspecting welfare provision in boarding schools, residential special schools and accommodation of students under
More informationFertility Services Commissioning Policy
Fertility Services Commissioning Policy NEE CCG Policy Reference: Where patients have commenced treatment in any cycle prior to this version becoming effective, they are subject to the eligibility criteria
More informationFertility treatment in trends and figures
Fertility treatment in 2010 trends and figures Contents Page No: Foreword by the Chair of the HFEA 3 Summary 4 Section 1: Overview How many fertility clinics were there in the UK in 2010? 6 How many women
More informationConsent for Pre-Implantation Genetic Diagnosis (PGD), Embryo Biopsy and Disposition
Consent for Pre-Implantation Genetic Diagnosis (PGD), Embryo Biopsy and Disposition Book Number Patient Name (Please print): Patient, IVFNE eivf Number: Partner Name (Please print, if applicable): Partner,
More informationInformation about cases being considered by the Case Examiners
Information about cases being considered by the Case Examiners 13 October 2016 1 Contents Purpose... 3 What should I do next?... 3 Background... 4 Criteria that Case Examiners will consider... 5 Closing
More informationNew Premises Inspection Report. Assisted Conception Unit Chelsea and Westminster Hospital. Centre Date of Inspection: 30 September 2009
New Premises Inspection Report Assisted Conception Unit Chelsea and Westminster Hospital Centre 0158 Date of Inspection: 30 September 2009 Date of Executive Licence Panel: 23 October 2009 Version: 1 Page
More informationDirections given under the Human Fertilisation and Embryology Act 1990 as amended. Ref: 0006 Version: 4
Directions given under the Human Fertilisation and Embryology Act 1990 as amended Import and export of gametes and embryo Ref: 0006 Version: 4 These Directions are: GENERAL DIRECTIONS Sections of the Act
More informationPGS & PGD. Preimplantation Genetic Screening Preimplantation Genetic Diagnosis
1 PGS & PGD Preimplantation Genetic Screening Preimplantation Genetic Diagnosis OUR MISSION OUR MISSION CooperGenomics unites pioneering leaders in reproductive genetics, Reprogenetics, Recombine, and
More informationWomen s consent to treatment and storage form (IVF and ICSI)
Women s consent to treatment and storage form (IVF and ICSI) HFEA WT form About this form This form is produced by the Human Fertilisation and Embryology Authority (HFEA), the UK s independent regulator
More informationTrust Policy 218 Ionising Radiation Safety Policy
Trust Policy 218 Ionising Radiation Safety Policy Purpose Date Version August 2016 7 To ensure that Plymouth Hospitals NHS Trust complies with all relevant legislation with regard to the use of ionising
More informationIPC Athletics. Classification Rules and Regulations
I P C AT H L E T I C S IPC Athletics Classification Rules and Regulations September 2011 IPC ATHLETICS CLASSIFICATION RULES AND REGULATIONS The IPC Athletics Classification Rules and Regulations are integral
More informationFertility Policy. December Introduction
Fertility Policy December 2015 Introduction Camden Clinical Commissioning Group (CCG) is responsible for commissioning a range of health services including hospital, mental health and community services
More informationPolicy updated: November 2018 (approved by Haringey and Islington s Executive Management Team on 5 December 2018)
Islington CCG Fertility Policy First approved: 29 January 2015 Policy updated: November 2018 (approved by Haringey and Islington s Executive Management Team on 5 December 2018) Introduction Islington CCG
More informationNational curriculum tests maladministration procedures. March 2007 QCA/07/3097
National curriculum tests maladministration procedures March 2007 QCA/07/3097 Contents 1. Purpose of document... 3 2. Scope... 4 3. General principles of national curriculum tests maladministration investigations...
More informationHaringey CCG Fertility Policy April 2014
Haringey CCG Fertility Policy April 2014 1 SUMMARY This policy describes the clinical pathways and entry criteria for Haringey patients wishing to access NHS funded fertility treatment. 2 RESPONSIBLE PERSON:
More informationNursing and Midwifery Council Fitness to Practise Committee. Substantive Order Review Meeting
Nursing and Midwifery Council Fitness to Practise Committee Substantive Order Review Meeting 18 March 2019 Nursing and Midwifery Council, 2 Stratford Place, Montfichet Road, London, E20 1EJ Name of registrant:
More information17. Storage of gametes and embryos
17. Storage of gametes and embryos This guidance note contains: Mandatory requirements Extracts from the HFE Act 1990 (as amended) Extracts from licence conditions Reference to relevant HFEA Directions
More informationNHS FUNDED TREATMENT FOR SUBFERTILITY. ELIGIBILITY CRITERIA POLICY GUIDANCE/OPTIONS FOR CCGs
NHS FUNDED TREATMENT FOR SUBFERTILITY ELIGIBILITY CRITERIA POLICY GUIDANCE/OPTIONS FOR CCGs CONTENTS Page 1. INTRODUCTION 2 2. GENERAL PRINCIPLES 2 3. DEFINITION OF SUBFERTILITY AND TIMING OF ACCESS TO
More informationDarwin Marine Supply Base HSEQ Quality Management Plan
Darwin Marine Supply Base HSEQ Quality Management Plan REVISION SUMMARY Revision Date Comment Authorised 0 29.9.13 Initial input JC 1 12.1.15 General Review JC 2 3 4 5 6 7 8 9 Revision Log Revision No
More informationCOUPLE INFORMATION SHEET AND INFORMED CONSENT FORM
Hyaluronic Acid Binding Sperm selection for ICSI (Intracytoplasmic Sperm Injection) COUPLE INFORMATION SHEET AND INFORMED CONSENT FORM We invite you to take part in a research study called HABSelect Before
More informationCancer Improvement Plan Update. September 2014
Cancer Improvement Plan Update September 2014 1 Contents Page 1. Introduction 3 2. Key Achievements 4-5 3. Update on Independent Review Recommendations 6-13 4. Update on IST Recommendations 14-15 5. Update
More informationThis paper outlines the engagement activity that took place, and provides key themes from the 57 written responses received.
Agenda item: 5.4 Subject: Presented by: Prepared by: Submitted to: Specialist Fertility Services Dr Dustyn Saint SNCCG Commissioning Team SNCCG Communications and Engagement Team SNCCG Governing Body Date:
More informationSt Helens CCG NHS Funded Treatment for Subfertility Policy 2015/16
St Helens CCG NHS Funded Treatment for Subfertility Policy 2015/16 1 Standard Operating Procedure St Helens CCG NHS Funded Treatment for Sub Fertility Policy Version 1 Implementation Date May 2015 Review
More informationAUDIT TOOL FOR SELF INSPECTION OF COMPLIANCE WITH QUALITY MANAGEMENT SYSTEM FOR PATIENT GROUP DIRECTIONS
AUDIT TOOL FOR DISPENSING SERVICES COMPILED BY: Lynn Morrison ISSUE 1 CHECKED BY: Colette Byrne NUMBER: ISSUE DATE: 01.12.07 SUPERSEDES: NEW REVIEW DATE: 01.12.09 AUDIT TOOL FOR SELF INSPECTION OF COMPLIANCE
More informationIntegrated Cancer Services Action Plan. Colchester Hospital University NHS Foundation Trust 31 March 2014
Integrated Cancer Services Action Plan Colchester Hospital University NHS Foundation Trust 31 March KEY Implemented, clearly evidenced and externally approved On Track to deliver Some issues narrative
More informationHALTON CLINICAL COMMISSIONING GROUP NHS FUNDED TREATMENT FOR SUBFERTILITY. CONTENTS Page
HALTON CLINICAL COMMISSIONING GROUP NHS FUNDED TREATMENT FOR SUBFERTILITY CONTENTS Page 1. INTRODUCTION 2 2. GENERAL PRINCIPLES 2 3. DEFINITION OF SUBFERTILITY AND TIMING OF ACCESS TO TREATMENT 3 4. DEFINITION
More informationAccess to IVF. Help us decide Discussion paper. South Central Specialised Commissioning Group C - 1
Access to IVF Help us decide Discussion paper South Central Specialised Commissioning Group 1 C - 1 Access to IVF treatment Contents 1. Background 3 2. Developing a single policy for NHS South Central..4
More informationCouples Information Leaflet
Couples Information Leaflet This project was funded by the National Institute for Health Research, Health Technology Assessment Programme (project number 13/115/82) You are due to undergo in vitro fertilisation
More informationNEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES
SOP details SOP title: SOP number: SOP category: Version number: 03 Version date: 19 December 2016 Effective date: 19 January 2017 Revision due date: 19 January 2020 NEWCASTLE CLINICAL TRIALS UNIT STANDARD
More informationRAH s Regional Fertility & Women s Endocrine Clinic FAQs
RAH s Regional Fertility & Women s Endocrine Clinic FAQs What changes are being made to the Regional Fertility & Women s Endocrine Clinic at the Lois Hole Hospital for Women in the Royal Alexandra Hospital
More informationApproved January Waltham Forest CCG Fertility policy
Approved January 2015 Waltham Forest CCG Fertility policy Contents 1 Introduction 1 2 Individual Funding Requests 1 2.1 Eligibility criteria 1 2.2 Number of cycles funded 2 2.3 Treatment Pathway 3 Page
More informationNote: This updated policy supersedes all previous fertility policies and reflects changes agreed by BHR CCGs governing bodies in June 2017.
Fertility Policy 10 July 2017 Note: This updated policy supersedes all previous fertility policies and reflects changes agreed by BHR CCGs governing bodies in June 2017. Introduction BHR CCGs are responsible
More informationFriday, 25 August 2017 HFEA, 10 Spring Gardens, London SW1A 2BU
Friday, 25 August 2017 HFEA, 10 Spring Gardens, London SW1A 2BU Panel members Hannah Verdin (Chair) Anna Coundley Howard Ryan Head of Regulatory Policy Information Access and Policy Manager Report Developer
More informationIT and Information Acceptable Use Policy
BMI IMpol04 Information Management IT and Information Acceptable Use Policy This is a controlled document and whilst this document may be printed, the electronic version posted on the intranet/shared drive
More informationLEAF Marque Assurance Programme
Invisible ISEAL Code It is important that the integrity of the LEAF Marque Standard is upheld therefore the LEAF Marque Standards System has an Assurance Programme to ensure this. This document outlines
More informationQuality Management in PCR. Sioban SenGupta UCL Centre for PGD UK
Quality Management in PCR Sioban SenGupta UCL Centre for PGD UK Outline 5.2 Accommodation & environmental conditions 5.3 Laboratory equipment 5.4 Pre-examination procedures 5.5 Examination procedures 5.6
More informationSTEM CELL RESEARCH: MEDICAL PROGRESS WITH RESPONSIBILITY
STEM CELL RESEARCH: MEDICAL PROGRESS WITH RESPONSIBILITY A REPORT FROM THE CHIEF MEDICAL OFFICER S EXPERT GROUP REVIEWING THE POTENTIAL OF DEVELOPMENTS IN STEM CELL RESEARCH AND CELL NUCLEAR REPLACEMENT
More informationMen s consent to the use and storage of sperm or embryos for surrogacy
HFEA MSG form Men s consent to the use and storage of sperm or embryos for surrogacy About this form This form is produced by the Human Fertilisation and Embryology Authority (HFEA), the UK s independent
More informationHUMAN FERTILISATION AND EMBRYOLOGY AUTHORITY MINUTES OF THE SCIENTIFIC AND CLINICAL ADVANCES ADVISORY COMMITTEE MEETING
HUMAN FERTILISATION AND EMBRYOLOGY AUTHORITY MINUTES OF THE SCIENTIFIC AND CLINICAL ADVANCES ADVISORY COMMITTEE MEETING held at Etc Venues, Bonhill House, 1-3 Bonhill Street, London EC2A4BX 4 th June 2014
More informationStrategy Strategic delivery: Setting standards Increasing and informing choice. Details: Output: Demonstrating efficiency economy and value
Strategy 2017-20 Strategic delivery: Setting standards Increasing and informing choice Demonstrating efficiency economy and value Details: Meeting Authority Agenda item 7 Paper number HFEA (11/05/2016)
More informationBromley CCG Assisted Conception Funding Form Checklist for Eligibility Criteria for NHS funding of Assisted Conception
Bromley CCG Assisted Conception Funding Form Checklist for Eligibility Criteria for NHS funding of Assisted Conception This form is for the use of administrators of Assisted Conception Units to notify
More informationLAB5 EDITION 2 NOVEMBER 2012
2007 LAB5 EDITION 2 NOVEMBER 2012 Reporting Calibration Results JH CONTENTS SECTION PAGE 1 Introduction 2 2 UKAS calibration accreditation symbol 3 3 General guidance for the presentation of calibration
More informationDo it Once, Do it Right
Do it Once, Do it Right Craig Reisser Andrea Speck-Zulak Families Through Surrogacy 2016 Founded in 1989 - more than 25 years building families patients from 40 countries One of the largest IVF clinics
More informationTHE LAW - CONCEPTION USING DONOR EGGS OR SPERM
Assisted Conception Unit 11 th Floor, Tower Wing Guy s Hospital, Great Maze Pond London SE1 9RT Tel:.020 7188 2300 Fax: 020 7188 0490 THE LAW - CONCEPTION USING DONOR EGGS OR SPERM Introduction If you
More informationUnderstanding eggs, sperm and embryos. Marta Jansa Perez Wolfson Fertility Centre
Understanding eggs, sperm and embryos Marta Jansa Perez Wolfson Fertility Centre What does embryology involve? Aims of the embryology laboratory Creation of a large number of embryos and supporting their
More informationFERTILITY SERVICE POLICY
FERTILITY SERVICE POLICY Page 1 of 8 FERTILITY SERVICE POLICY Please note that all Clinical Commissioning policies are currently under review and elements within the individual policies may have been replaced
More informationInternational Standard for Athlete Evaluation. July 2015
International Standard for Athlete Evaluation July 2015 International Paralympic Committee Adenauerallee 212-214 Tel. +49 228 2097-200 www.paralympic.org 53113 Bonn, Germany Fax +49 228 2097-209 info@paralympic.org
More informationCommittee Paper SCAAC(05/09)01. ICSI guidance. Hannah Darby and Rachel Fowler
Committee Paper Committee: Scientific and Clinical Advances Advisory Committee Meeting Date: 12 May 2009 Agenda Item: 4 Paper Number: SCAAC(05/09)01 Paper Title: ICSI guidance Author: Hannah Darby and
More informationYour consent to the storage of your eggs or sperm
Your consent to the storage of your eggs or sperm HFEA GS form About this form This form is produced by the Human Fertilisation and Embryology Authority (HFEA), the UK s independent regulator of fertility
More informationCOMMISSIONING POLICY FOR IN VITRO FERTILISATION (IVF)/ INTRACYTOPLASMIC SPERM INJECTION (ICSI) WITHIN TERTIARY INFERTILITY SERVICES V2.
COMMISSIONING POLICY FOR IN VITRO FERTILISATION (IVF)/ INTRACYTOPLASMIC SPERM INJECTION (ICSI) WITHIN TERTIARY INFERTILITY SERVICES V2.3 2017 Agreed at Cannock Chase CCG Signature: Designation: Chair of
More informationD D M M Y Y D D M M Y Y. For clinic use only (optional) MD PNT only (gender-neutral): version 1; 3 April 2017
This form is produced by the Human Fertilisation and Embryology Authority (HFEA), the UK s independent regulator of fertility treatment and human embryo research. For more information about us, visit www.hfea.gov.uk.
More informationFitness to Practise Committee Rules and Practice Direction Revised September 2012
Fitness to Practise Committee Rules and Practice Direction Revised September 2012 Table of Contents RULE 1 DEFINITIONS 1 RULE 2 ELECTRONIC HEARINGS 2 RULE 3 DUTY OF EXPERT 4 PRACTICE DIRECTION 5 No. 1
More informationSPECIALIST FERTILITY SERVICES CLINICAL CRITERIA & CONTRACT AWARD
AGENDA ITEM 8 GOVERNING BODY MEETING IN PUBLIC ON 25 TH SEPTEMBER 2014 SPECIALIST FERTILITY SERVICES CLINICAL CRITERIA & CONTRACT AWARD Date of the meeting 25 th September 2014 Author Sponsoring Board
More informationRIC Information for Patients
RIC Information for Patients RIC Information for Patients 1. Pregnancy and the immune system From the implantation of a fertilised egg to the delivery of a healthy baby, the maternal immune system has
More information